Calithera Biosciences, Inc. (NASDAQ:CALA) Q3 2018 Earnings Conference Call Transcript

Nov 07, 2018 • 05:00 pm ET

Previous

Calithera Biosciences, Inc. (NASDAQ:CALA) Q3 2018 Earnings Conference Call Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good day, ladies and gentlemen, and welcome to the Calithera Biosciences, Inc. Third Quarter 2018 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call may be recorded.

I would now like to introduce your host for today's conference, Ms. Jennifer McNealey, Vice President of Investor Relations. Ma'am, you may begin.

Executive
Jennifer McNealey

Thank you, Geral(ph). Good afternoon, everyone. Welcome to our third quarter 2018 conference call. Joining me today are Susan Molineaux, our Founder, President and CEO; Stephanie Wong, Senior Vice President of Finance; and Keith Orford, Senior Vice President of Clinical Development. We've issued our press release and it can be accessed through our website at calithera.com.

(Forward-Looking Cautionary Statements) Please note that this call is being recorded. And with that, I will turn the call over to Susan.

Executive
Susan Molineaux

Thanks Jennifer and good afternoon everyone. Thank you for joining us today on our third quarter 2018 conference call. At Calithera, we are building an integrated biotechnology Company that develops novel small molecule oncometabolism drugs. Drugs, that are targeting tumor and immune cell metabolism pathways for the treatment of cancer and other diseases.

By building a pipeline of novel therapeutic product candidates, we are creating multiple opportunities to positively impact clinical outcomes for patients and drive development programs towards commercialization. In the third quarter, we continued to execute our clinical development plans for our novel oral glutaminase inhibitor CB-839. We are primarily focused on executing a clinical development path for CB-839 in renal cell carcinoma, which is enrolling in two randomized double-blind trials in renal cell carcinoma now.

We also announced two clinical collaborations to evaluate Pfizer's CDK4/6 palbociclib, also known as IBRANCE; and the dual mechanism PARP inhibitor, talazoparib, also known as TALZENNA, each in combination with our glutaminase inhibitor, CB-839. This allows us to continue maximizing the potential for CB-839 in other solid tumor indications.

Our arginase inhibitor, a small molecule immuno-oncology therapeutic, continues to progress in the clinic. INCB001158 is being evaluated in 2 clinical trials for the treatment of patients with solid tumors, both as a monotherapy and in combination with immunotherapy or chemotherapy. 1158 is being developed as part of a collaboration and license agreement with Incyte. And data from 1158 is expected to be presented at a medical meeting in the first half of 2019.

We've also deepened our pipeline with two novel programs entering clinical development next year. Our fully integrated drug discovery team continues to produce novel drug candidates with the potential to be highly differentiated new therapies in areas of unmet need. This includes our two new candidates, CB-280, a novel arginase inhibitor for the treatments of cystic fibrosis. And CB-708, an oral small molecule CD73 inhibitor for the treatment of cancer.

As each of our programs move forward in development, we look forward to a number of important milestones and value inflection points in the near term. In 2019, we look forward to achieving the following goals. First, for CB-839, we expect to fully enroll the ENTRATA trial in the fourth